This study retrospectively analyzed the effect of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for ESCC, and the results showed that 82.9% of patients were effective for chemotherapy, suggesting that this regimen is one of the effective neoadjuvant therapies for ESCC. This evidence concerns the gene ALB and esophageal squamous cell carcinoma.